Journal: Scientific Reports

Article Title: Retention of embryonic positional identity signatures in the adult sheep tail: evidence from HOXB13 spatial RNA expression gradients

doi: 10.1038/s41598-026-42438-7

Figure Lengend Snippet: Validation of RNA-seq–derived gene expression patterns in tail skin using TaqMan qPCR. (A) RNA-seq log2 fold-change values for selected differentially expressed genes ( HOXB13 , SP8 , ALOX15 , LOXL4 , AGT , HOXA13 , ACSM2B ) across three anatomical positions (tail base, mid-tail, tail tip) in rams with A/A and D/D HOXB13 genotypes. (B) TaqMan qPCR validation of gene expression profiles in tail skin for the same gene set and anatomical locations. Expression changes relative to the tail base are shown as log2 fold-changes. (C) TaqMan qPCR analysis of the same genes in tail bone tissue at the same anatomical positions. Patterns observed in bone samples closely mirrored those found in skin, especially for HOXB13 , HOXA13 , and ALOX15 . For all panels, mean expression changes are shown separately for A/A and D/D genotypes. Genes identified as up- or down-regulated in the RNA-seq data displayed concordant expression trends in qPCR validations.

Article Snippet: For the target genes, the following TaqMan Gene Expression Assays were used: ALOX15 (Oa04833777_m1), HOXA13 (Oa04668307_m1), ACSM2B (Oa04721289_m1), AGT (Oa04814695_m1), LOXL4 (Oa04673501_m1), and SP8 , which was custom-designed.

Techniques: Biomarker Discovery, RNA Sequencing, Derivative Assay, Gene Expression, Expressing

Journal: Molecular Therapy. Nucleic Acids

Article Title: A computational model-powered platform to inform the development of GalNAc-conjugated siRNA therapeutics

doi: 10.1016/j.omtn.2026.102936

Figure Lengend Snippet: A workflow of this study (A) Overview of the mechanism of action of N-acetylgalactosamine-small interfering RNA (GalNAc-siRNA) and the seven approved GalNAc-SiRNA drugs collected in this study. (B) Schematic structure of the developed computational model for a GalNAc-siRNA. (C) Schematic workflow of the model informed GalNAc-siRNA development powered by the established computational platform.

Article Snippet: Finally, the platform was utilized to support the development of an investigational new angiotensinogen ( AGT )-silencing GalNAc-siRNA, termed SAL0132 (developed by Shenzhen Salubris Pharmaceuticals Co., Ltd), from preclinic rats and monkey to clinical studies.

Techniques: Small Interfering RNA

Journal: Biomolecules & Therapeutics

Article Title: γ-Oryzanol Ameliorates Endothelial Replicative Senescence via Downregulation of SGLT2 Expression to Attenuate NADPH-Driven Oxidative Stress

doi: 10.4062/biomolther.2025.133

Figure Lengend Snippet: γ-Orz downregulates SGLT2 expression and reduces NADPH oxidase-induced oxidative stress. (A) Representative blots of SGLT2, p22 phox , NOX2, and eNOS in P3 ECs in presence of γ-Orz (3, 10 µM). (B-E) Cumulative data for expression of SGLT2, p22 phox , NOX2, and eNOS respectively. Data are expressed as mean ± SEM (n=3). # p <0.05, ## p <0.01 vs. P1; * p <0.05; ** p <0.01 vs. P3.

Article Snippet: The protein was loaded onto a 10% sodium dodecyl sulfate–polyacrylamide gel and separated by electrophoresis, then transferred to a polyvinylidene difluoride membrane that was blocked with 5% bovine serum albumin (BSA) for 1 h and incubated overnight at 4°C with primary antibodies against β-actin (sc-47778, 1:5000; Santa Cruz Biotechnology); p53 (sc-6243, 1:1000; Santa Cruz Biotechnology); p21 (sc-397, 1:1000; Santa Cruz Biotechnology); p16 (sc-1661, 1:1000; Santa Cruz Biotechnology); p22 phox (sc-271968, 1:1000; Santa Cruz Biotechnology); SGLT2 (AGT-032, 1:1000, Alomone labs); eNOS (cat. no. 610297, 1:1000; BD biosciences); NOX2 (cat. no. 19013-1-AP, 1:1000; Protein tech); diluted in 5% BSA.

Techniques: Expressing

Journal: Biomolecules & Therapeutics

Article Title: γ-Oryzanol Ameliorates Endothelial Replicative Senescence via Downregulation of SGLT2 Expression to Attenuate NADPH-Driven Oxidative Stress

doi: 10.4062/biomolther.2025.133

Figure Lengend Snippet: Graphical abstract illustrating the protective effects of γ-Orz against replicative senescence in PCAECs. γ-Orz suppresses SGLT2 expression, leading to reduced NADPH oxidase-mediated ROS production, restoration of eNOS levels, and inhibition of the p53/p21/p16 signaling pathway. These effects collectively decrease SA-β-gal activity, improve cell proliferation, and delay ECs senescence, thereby contributing to the mitigation of vascular aging. Abbreviations: γ-Orz, γ-oryzanol; PCAECs, porcine coronary artery endothelial cells; SGLT2, sodium-glucose co-transporter 2; NADPH oxidase, nicotinamide adenine dinucleotide phosphate oxidase; ROS, reactive oxygen species; eNOS, endothelial nitric oxide synthase; SA-β-gal, senescence-associated beta-galactosidase; ECs, endothelial cells.

Article Snippet: The protein was loaded onto a 10% sodium dodecyl sulfate–polyacrylamide gel and separated by electrophoresis, then transferred to a polyvinylidene difluoride membrane that was blocked with 5% bovine serum albumin (BSA) for 1 h and incubated overnight at 4°C with primary antibodies against β-actin (sc-47778, 1:5000; Santa Cruz Biotechnology); p53 (sc-6243, 1:1000; Santa Cruz Biotechnology); p21 (sc-397, 1:1000; Santa Cruz Biotechnology); p16 (sc-1661, 1:1000; Santa Cruz Biotechnology); p22 phox (sc-271968, 1:1000; Santa Cruz Biotechnology); SGLT2 (AGT-032, 1:1000, Alomone labs); eNOS (cat. no. 610297, 1:1000; BD biosciences); NOX2 (cat. no. 19013-1-AP, 1:1000; Protein tech); diluted in 5% BSA.

Techniques: Expressing, Inhibition, Activity Assay